Tasly Pharmaceutical Group Co (SHSE:600535) Piotroski F-Score: 7 (As of Jul. 14, 2026) — 40% Above Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:600535 Tasly Pharmaceutical Group Co Ltd SHSE:600535
79 GF Score
Price ¥14.59
GF Value ¥15.06
Valuation Fairly Valued
! 1 Warning Sign
View Full Analysis

What is Tasly Pharmaceutical Group Co Piotroski F-Score?

Tasly Pharmaceutical Group Co SHSE:600535 +1.46% 79 Piotroski F-Score is 7 as of Jul. 14, 2026, which is 40% above its 10-year median of 5.00. GuruFocus rates SHSE:600535 with a GF Score™ of 79/100 and a GF Value™ of ¥15.06 (Fairly Valued). The stock has 1 warning sign investors should review. Among 979 Drug Manufacturers companies, Tasly Pharmaceutical Group Co ranks better than 91.93% on this metric.

Good Sign:

Piotroski F-Score is 7, indicates a very healthy situation.

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Tasly Pharmaceutical Group Co has an F-score of 7. It is a good or high score, which usually indicates a very healthy situation.

The historical rank and industry rank for Tasly Pharmaceutical Group Co's Piotroski F-Score or its related term are showing as below:

SHSE:600535' s Piotroski F-Score Range Over the Past 10 Years
Min: 3   Med: 5   Max: 9
Current: 7

During the past 13 years, the highest Piotroski F-Score of Tasly Pharmaceutical Group Co was 9. The lowest was 3. And the median was 5.

Tasly Pharmaceutical Group Co  (SHSE:600535) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Tasly Pharmaceutical Group Co Piotroski F-Score Related Terms


Tasly Pharmaceutical Group Co Piotroski F-Score Historical Data

* Premium members only.

The historical data trend for Tasly Pharmaceutical Group Co's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tasly Pharmaceutical Group Co Piotroski F-Score Chart

Tasly Pharmaceutical Group Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Piotroski F-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.00 4.00 7.00 6.00 7.00

Tasly Pharmaceutical Group Co Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.00 7.00 9.00 7.00 7.00

SHSE:600535 vs ZTS, UTHR: Piotroski F-Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Tasly Pharmaceutical Group Co's Piotroski F-Score, along with its competitors' market caps and Piotroski F-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tasly Pharmaceutical Group Co Piotroski F-Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Tasly Pharmaceutical Group Co's Piotroski F-Score distribution charts can be found below:

* The bar in red indicates where Tasly Pharmaceutical Group Co's Piotroski F-Score falls into.


SHSE:600535
79GF Score
Tasly Pharmaceutical Group Co Ltd SHSE:600535
Piotroski F-Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Mar26) TTM:Last Year (Mar25) TTM:
Net Income was 460.387 + 209.677 + 120.589 + 370.242 = ¥1,161 Mil.
Cash Flow from Operations was 1151.962 + 83.025 + 552.134 + 464.614 = ¥2,252 Mil.
Revenue was 2233.322 + 2022.464 + 1925.805 + 2164.797 = ¥8,346 Mil.
Gross Profit was 1520.252 + 1338.498 + 1278.916 + 1541.108 = ¥5,679 Mil.
Average Total Assets from the begining of this year (Mar25)
to the end of this year (Mar26) was
(14996.747 + 15448.597 + 14957.314 + 15339.72 + 15693.754) / 5 = ¥15287.2264 Mil.
Total Assets at the begining of this year (Mar25) was ¥14,997 Mil.
Long-Term Debt & Capital Lease Obligation was ¥242 Mil.
Total Current Assets was ¥8,624 Mil.
Total Current Liabilities was ¥2,321 Mil.
Net Income was 367.097 + 179.893 + 113.385 + 314.31 = ¥975 Mil.

Revenue was 2323.084 + 2090.82 + 2035.582 + 2054.886 = ¥8,504 Mil.
Gross Profit was 1573.078 + 1367.887 + 1388.944 + 1368.817 = ¥5,699 Mil.
Average Total Assets from the begining of last year (Mar24)
to the end of last year (Mar25) was
(17517.01 + 17604.264 + 16834.745 + 14976.295 + 14996.747) / 5 = ¥16385.8122 Mil.
Total Assets at the begining of last year (Mar24) was ¥17,517 Mil.
Long-Term Debt & Capital Lease Obligation was ¥203 Mil.
Total Current Assets was ¥7,369 Mil.
Total Current Liabilities was ¥2,455 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Tasly Pharmaceutical Group Co's current Net Income (TTM) was 1,161. ==> Positive ==> Score 1.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Tasly Pharmaceutical Group Co's current Cash Flow from Operations (TTM) was 2,252. ==> Positive ==> Score 1.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Mar25)
=1160.895/14996.747
=0.07740979

ROA (Last Year)=Net Income/Total Assets (Mar24)
=974.685/17517.01
=0.0556422

Tasly Pharmaceutical Group Co's return on assets of this year was 0.07740979. Tasly Pharmaceutical Group Co's return on assets of last year was 0.0556422. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Tasly Pharmaceutical Group Co's current Net Income (TTM) was 1,161. Tasly Pharmaceutical Group Co's current Cash Flow from Operations (TTM) was 2,252. ==> 2,252 > 1,161 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Mar26)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar25 to Mar26
=241.989/15287.2264
=0.01582949

Gearing (Last Year: Mar25)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Mar24 to Mar25
=202.87/16385.8122
=0.01238083

Tasly Pharmaceutical Group Co's gearing of this year was 0.01582949. Tasly Pharmaceutical Group Co's gearing of last year was 0.01238083. ==> Last year is lower than this year ==> Score 0.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Mar26)=Total Current Assets/Total Current Liabilities
=8623.823/2321.113
=3.71538266

Current Ratio (Last Year: Mar25)=Total Current Assets/Total Current Liabilities
=7368.827/2455.322
=3.00116522

Tasly Pharmaceutical Group Co's current ratio of this year was 3.71538266. Tasly Pharmaceutical Group Co's current ratio of last year was 3.00116522. ==> This year's current ratio is higher. ==> Score 1.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Tasly Pharmaceutical Group Co's number of shares in issue this year was 1494.115. Tasly Pharmaceutical Group Co's number of shares in issue last year was 1493.867. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=5678.774/8346.388
=0.68038701

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=5698.726/8504.372
=0.67009369

Tasly Pharmaceutical Group Co's gross margin of this year was 0.68038701. Tasly Pharmaceutical Group Co's gross margin of last year was 0.67009369. ==> This year's gross margin is higher. ==> Score 1.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Mar25)
=8346.388/14996.747
=0.55654656

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Mar24)
=8504.372/17517.01
=0.48549222

Tasly Pharmaceutical Group Co's asset turnover of this year was 0.55654656. Tasly Pharmaceutical Group Co's asset turnover of last year was 0.48549222. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=1+1+1+1+0+1+0+1+1
=7

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Tasly Pharmaceutical Group Co has an F-score of 7. It is a good or high score, which usually indicates a very healthy situation.

Frequently Asked Questions Learn more about Piotroski F-Score →
What does a Piotroski F-Score of 7 mean?
Tasly Pharmaceutical Group Co (SHSE:600535) has a Piotroski F-Score of 7 as of Jul. 14, 2026. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Tasly Pharmaceutical Group Co and its competitors. This is 40% above median its historical median of 5.00. Over the past decade, Tasly Pharmaceutical Group Co's Piotroski F-Score has ranged from 3.00 to 9.00. According to the industry distribution chart, Tasly Pharmaceutical Group Co ranks #79 out of 979 companies in the Drug Manufacturers industry, placing it in the top 8.1%.
Is Tasly Pharmaceutical Group Co's Piotroski F-Score too high?
Tasly Pharmaceutical Group Co's current Piotroski F-Score of 7 is 40% above median its 10-year median of 5.00. Over the past 10 years, this metric has ranged from a low of 3.00 to a high of 9.00. The Drug Manufacturers industry median Piotroski F-Score is 5.00. Tasly Pharmaceutical Group Co's value of 7 is 40% above this industry median. Based on the distribution chart, Tasly Pharmaceutical Group Co ranks #79 out of 979 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Tasly Pharmaceutical Group Co has a GF Score™ of 79/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Tasly Pharmaceutical Group Co's Piotroski F-Score compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Tasly Pharmaceutical Group Co ranks #79 out of 979 companies for Piotroski F-Score. This places Tasly Pharmaceutical Group Co in the top 8% of its industry — outperforming the majority of peers. The industry median Piotroski F-Score is 5.00. Tasly Pharmaceutical Group Co's value of 7 is 40% above this benchmark. Historically, Tasly Pharmaceutical Group Co's own Piotroski F-Score has ranged from 3.00 to 9.00 over the past decade. While the company's 10-year median is 5.00 vs. the industry median of 5.00, Tasly Pharmaceutical Group Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Piotroski F-Score for a Drug Manufacturers company?
The median Piotroski F-Score among Drug Manufacturers companies is 5.00, based on 979 companies in the industry. Companies in the top quartile (top 25%) have a Piotroski F-Score significantly above this median, while those in the bottom quartile fall well below. However, Piotroski F-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Tasly Pharmaceutical Group Co's current Piotroski F-Score of 7 is 40% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Piotroski F-Score mean?
A high Piotroski F-Score can signal that a stock is expensive relative to its fundamentals. The Piotroski F-score grades a company's business operating strength from 0-9. View historical data on Tasly Pharmaceutical Group Co and its competitors. For the Drug Manufacturers industry, the median Piotroski F-Score is 5.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tasly Pharmaceutical Group Co's current Piotroski F-Score is 7, which is 40% above median its own 10-year median of 5.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tasly Pharmaceutical Group Co stock overvalued right now?
Based on GuruFocus' analysis, Tasly Pharmaceutical Group Co (SHSE:600535) is currently considered Fairly Valued. The stock's GF Value™ is ¥15.06, compared to a current price of ¥14.59 — trading 3.1% below its estimated fair value. The current Piotroski F-Score is 7, which is 40% above median its 10-year median of 5.00 and 40% above the Drug Manufacturers industry median of 5.00. Tasly Pharmaceutical Group Co's overall GF Score™ is 79/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Piotroski F-Score calculated?
Piotroski F-Score is calculated from a company's financial statements. For Tasly Pharmaceutical Group Co (SHSE:600535), the current Piotroski F-Score is 7 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Tasly Pharmaceutical Group Co (SHSE:600535) Overvalued in 2026?

Based on GuruFocus' analysis, Tasly Pharmaceutical Group Co stock appears to be undervalued. The current stock price of ¥14.59 is trading 3.1% below its estimated GF Value™ of ¥15.06. GuruFocus considers Tasly Pharmaceutical Group Co to be Fairly Valued.

Key valuation signals for SHSE:600535:

  • Piotroski F-Score: 7 (40% above median its 10-year median of 5.00)
  • GF Value™: ¥15.06 vs. price of ¥14.59 (3.1% below fair value)
  • GF Score™: 79/100 with 1 warning sign
  • Industry Position: 40% above the Drug Manufacturers median (#79 of 979)

No single metric tells the full story. See the SHSE:600535 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Tasly Pharmaceutical Group Co Business Description

Address 2 Pujihe Road East, Beichen District, Tasly TCM Garden, Tianjin, CHN, 300410
Tasly Pharmaceutical Group Co Ltd is a China-based company engaged in the manufacturing and distribution of pharmaceutical products. Its herbal medicines include Tasly Cerebral Care Granules and Tasly ICP. Its chemical medicines comprise of Ketotifen Fumarate Tablets, Thiamphenicol Capsules, Glucurolactone Tablets and Sulpiride Tablets. Some of the other products offered by the company include PharmceuticalSubstances & API, HerbalExtract, and Concentrated Herbal Granules.
79GF Score

Get the complete analysis for SHSE:600535

Piotroski F-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥14.59
Price
¥15.06
GF Value